Saturday 17 October 2026
Export SCYX’s income statement to Excel — free account
SCYNEXIS, Inc.
SCYX Healthcare Drug Manufacturers Specialty & Generic
SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024. In the quarter to June 2026, revenue fell 8.56%, EPS grew 156.3% and free cash flow fell 98.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.67
0.24
−6.14%
Follow SCYX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | 5 | 3 |
+8 more TTM periods Free account |
| (18.38%) | (53.39%) | (16.48%) | (53.29%) | ||
| (15.09%) | (33.69%) | (11.50%) | (33.71%) | ||
ROIC |
(110.72%) | 0.00% | (108.43%) | 0.00% | |
Return on Tangible Assets |
(20.30%) | (52.40%) | (24.85%) | (62.90%) | |
Average Days of Receivables |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.13) | (0.93) | (0.85) | (5.39) | |
Free Cash Flow |
(13.31) | (5.92) | (5.28) | (33.59) | |
| Other line items | |||||
Cash ROIC |
(10.99%) | (5.88%) | (5.90%) | (45.13%) | |
Accounts Receivable Turnover |
0.00 | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
127.51% | 0.00% | 108.15% | 751.94% | |
Selling, General and Administrative Expense of Revenue |
75.77% | 0.00% | 69.88% | 529.09% | |
Share Based Compensation of Revenue |
11.47% | 0.00% | 13.84% | 107.30% | |
Operating CF/Net income |
1.30 | 0.24 | 0.61 | 1.33 | |
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Revenue per Share |
1.74 | 0.00 | 3.30 | 0.47 | |
Operating CF per Share |
(1.13) | (0.93) | (0.85) | (5.39) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates